195 related articles for article (PubMed ID: 20604681)
1. CD40-targeted recombinant adenovirus significantly enhances the efficacy of antitumor vaccines based on dendritic cells and B cells.
Kim YS; Kim YJ; Lee JM; Han SH; Ko HJ; Park HJ; Pereboev A; Nguyen HH; Kang CY
Hum Gene Ther; 2010 Dec; 21(12):1697-706. PubMed ID: 20604681
[TBL] [Abstract][Full Text] [Related]
2. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model.
Tillman BW; Hayes TL; DeGruijl TD; Douglas JT; Curiel DT
Cancer Res; 2000 Oct; 60(19):5456-63. PubMed ID: 11034088
[TBL] [Abstract][Full Text] [Related]
3. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen.
Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
J Immunol; 2003 Oct; 171(8):4121-30. PubMed ID: 14530334
[TBL] [Abstract][Full Text] [Related]
4. Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule.
Pereboev AV; Nagle JM; Shakhmatov MA; Triozzi PL; Matthews QL; Kawakami Y; Curiel DT; Blackwell JL
Mol Ther; 2004 May; 9(5):712-20. PubMed ID: 15120332
[TBL] [Abstract][Full Text] [Related]
5. Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine.
Hangalapura BN; Oosterhoff D; de Groot J; Boon L; Tüting T; van den Eertwegh AJ; Gerritsen WR; van Beusechem VW; Pereboev A; Curiel DT; Scheper RJ; de Gruijl TD
Cancer Res; 2011 Sep; 71(17):5827-37. PubMed ID: 21747119
[TBL] [Abstract][Full Text] [Related]
6. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen.
Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
J Immunol; 2003 Mar; 170(6):2912-22. PubMed ID: 12626542
[TBL] [Abstract][Full Text] [Related]
7. [Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine].
Wang QY; Xu YF; Fan DS; Peng QL; Zhang T; Xu XM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):584-91. PubMed ID: 18051710
[TBL] [Abstract][Full Text] [Related]
8. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.
Báez-Astúa A; Herráez-Hernández E; Garbi N; Pasolli HA; Juárez V; Zur Hausen H; Cid-Arregui A
J Virol; 2005 Oct; 79(20):12807-17. PubMed ID: 16188983
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
[TBL] [Abstract][Full Text] [Related]
10. An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells.
Zhang L; Tang Y; Akbulut H; Zelterman D; Linton PJ; Deisseroth AB
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15101-6. PubMed ID: 14645711
[TBL] [Abstract][Full Text] [Related]
11. Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells.
Echeverria I; Pereboev A; Silva L; Zabaleta A; Riezu-Boj JI; Bes M; Cubero M; Borras-Cuesta F; Lasarte JJ; Esteban JI; Prieto J; Sarobe P
Hepatology; 2011 Jul; 54(1):28-37. PubMed ID: 21452282
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand.
Hung CF; Hsu KF; Cheng WF; Chai CY; He L; Ling M; Wu TC
Cancer Res; 2001 Feb; 61(3):1080-8. PubMed ID: 11221836
[TBL] [Abstract][Full Text] [Related]
13. Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus.
Hangalapura BN; Oosterhoff D; Aggarwal S; Wijnands PG; van de Ven R; Santegoets SJ; van den Tol MP; Hooijberg E; Pereboev A; van den Eertwegh AJ; Curiel DT; Scheper RJ; de Gruijl TD
J Immunother; 2010 Sep; 33(7):706-15. PubMed ID: 20664356
[TBL] [Abstract][Full Text] [Related]
14. Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7.
Dell K; Klein C; Gissmann L
Antivir Ther; 2008; 13(4):495-509. PubMed ID: 18672528
[TBL] [Abstract][Full Text] [Related]
15. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.
Arribillaga L; Echeverria I; Belsue V; Gomez T; Lozano T; Casares N; Villanueva L; Domingos-Pereira S; Romero PJ; Nardelli-Haefliger D; Hervás-Stubbs S; Sarobe P; Rodriguez MJ; Carrascosa JL; Zürcher T; Lasarte JJ
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581060
[TBL] [Abstract][Full Text] [Related]
16. Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70.
Zhou L; Zhu T; Ye X; Yang L; Wang B; Liang X; Lu L; Tsao YP; Chen SL; Li J; Xiao X
Hum Gene Ther; 2010 Jan; 21(1):109-19. PubMed ID: 19715402
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of murine bone marrow-derived dendritic cells infected with xenogeneic livin alpha recombinant adenoviral vectors against Lewis lung carcinoma.
Xie J; Xiong L; Tao X; Li X; Su Y; Hou X; Shi H
Lung Cancer; 2010 Jun; 68(3):338-45. PubMed ID: 19671483
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects.
Indrová M; Reinis M; Bubeník J; Jandlová T; Bieblová J; Vonka V; Velek J
Folia Biol (Praha); 2004; 50(6):184-93. PubMed ID: 15709713
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells.
Kikuchi T; Crystal RG
Hum Gene Ther; 1999 May; 10(8):1375-87. PubMed ID: 10365667
[TBL] [Abstract][Full Text] [Related]
20. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
Loskog A; Tötterman TH; Böhle A; Brandau S
Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
